Vaginal infections:
Indications for: BREXAFEMME
Vulvovaginal candidiasis.
Adult Dosage:
≥18yrs or post-menarchal: 300mg orally every 12hrs for 1 day. Concomitant strong CYP3A4 inhibitors: 150mg orally every 12hrs for 1 day.
Children Dosage:
<18yrs or pre-menarchal: not established.
BREXAFEMME Contraindications:
Pregnancy.
BREXAFEMME Warnings/Precautions:
Risk of fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 4 days after the last dose. Exclude pregnancy status prior to initiation. Nursing mothers.
BREXAFEMME Classification:
Triterpenoid antifungal.
BREXAFEMME Interactions:
Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole); reduce ibrexafungerp dose. May be antagonized by strong or moderate CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St. John’s wort, long acting barbiturates, bosentan, efavirenz, etravirine); avoid concomitant use.
Adverse Reactions:
Diarrhea, nausea, abdominal pain, dizziness, vomiting.
Generic Drug Availability:
NO
How Supplied:
Blister packs—4
